Cargando…
吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析
BACKGROUND AND OBJECTIVE: Lung cancer in young patients (less or equal to 45 years) is relatively rare. We explored the efficacy and survival of Gefitinib for young patients with unknown epidermal growth factor receptor (EGFR) gene mutation of advanced lung adenocarcinoma. METHODS: The clinical data...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000448/ https://www.ncbi.nlm.nih.gov/pubmed/24854557 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.06 |